https://doi.org/10.4081/hmr.v2i7.417

PLiposomal doxorubicin: emergent data in lymphoproliferative disease

Vol. 2 No. 7: New Insights in Hematology, Venice (Italy), May 14-17, 2006
Published: June 8, 2009
Abstract Views: 138
PDF: 258
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

L Rigacci
support@pagepress.org
Doxorubicin is classified as an anthracycline antibiotic. Doxorubicin is an effective antineoplastic agent and is widely used as one of the components in multiple-drug chemotherapy in the treatment of Hodgkin’s lymphoma, aggressive non Hodgkin’s lymphomas, acute lymphoblastic leukaemia, metastatic breast carcinoma, ovarian carcinoma, lung carcinoma and sarcoma. However, the clinical utility of the drug is limited by irreversible cardiomiopathy. Doxorubicin-associated myocardial damage is cumulative, dose-related, progressive and may lead to congestive heart failure (CHF).1 The incidence of CHF varies as the results of differences in study populations, treatment regimens, and the duration of follow-up.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Rigacci, L. (2009). PLiposomal doxorubicin: emergent data in lymphoproliferative disease. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.417
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).